Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies
Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies
09/15/20, 12:22 PM
Location
menlo parkMoney raised
$47 million
Round Type
series a
Hexagon Bio, Inc. ("Hexagon"), a biotechnology company turning nature's genomes into medicines, today announced that it has closed $47 million in Series A financing. The round was led by The Column Group, with participation from 8VC and Two Sigma Ventures. Tod Smeal, formerly of Eli Lilly, Pfizer and SUGEN, will join as Chief Scientific Officer as the company adds drug discovery capabilities to complement its interdisciplinary platform for molecule identification.
Company Info
Location
menlo park, california, united states
Additional Info
Hexagon Bio is a drug discovery company enabled by a novel understanding of natural product evolution. Hexagon's highly interdisciplinary platform uses data science, genomics, synthetic biology and automation to discover potent, evolutionarily refined small molecules and their protein targets directly from fungal genomes. Hexagon develops these molecules into therapeutics to combat human disease. Hexagon launched in 2017 and has raised $55 million to date from The Column Group, 8VC, Two Sigma Ventures, and others.